Mucoangin Citron
Ambroxol Lozenge for Fast-Acting Sore Throat Relief
Quick Facts About Mucoangin Citron
Key Takeaways About Mucoangin Citron
- Mucoangin Citron contains 20 mg ambroxol hydrochloride and provides local anaesthetic relief for acute sore throat pain in adults and children over 12 years.
- Pain relief begins within 20 minutes and lasts at least 3 hours per lozenge, with a maximum of 6 lozenges per day.
- Do not use for more than 3 consecutive days – consult a doctor if symptoms persist or worsen, or if you develop a high fever.
- Not suitable during pregnancy or breastfeeding, as ambroxol crosses the placenta and passes into breast milk.
- Seek immediate medical attention if you experience signs of allergic reaction (swelling of face, lips, or throat) or any skin rash while using this medicine.
What Is Mucoangin Citron and What Is It Used For?
Mucoangin Citron belongs to a group of medicines used to treat sore throat (pharyngitis). The active ingredient, ambroxol hydrochloride, is widely recognised for its mucolytic properties in oral and inhaled formulations. However, in lozenge form, ambroxol acts primarily as a local anaesthetic, providing direct pain relief to the inflamed throat tissue.
The local anaesthetic effect of ambroxol is attributed to its ability to block sodium channels in the sensory nerve fibres of the oropharyngeal mucosa. This mechanism is similar to that of established local anaesthetics such as lidocaine, though ambroxol also possesses anti-inflammatory properties that contribute to its therapeutic effect. Clinical studies have demonstrated that 20 mg ambroxol lozenges provide statistically significant pain relief compared to placebo, with a rapid onset of action within 20 minutes of administration.
Mucoangin Citron is specifically indicated for the symptomatic relief of pain associated with acute sore throat in adults and children over 12 years of age. Sore throat is one of the most common reasons for seeking medical advice and pharmacy consultations worldwide, with the majority of cases caused by viral upper respiratory tract infections. While most episodes of acute pharyngitis are self-limiting, the pain and discomfort can be significant, and effective symptomatic relief is an important aspect of patient care.
The lozenge formulation allows for prolonged contact between the active substance and the inflamed throat tissue, maximising the local anaesthetic effect. Each lozenge should be allowed to dissolve slowly in the mouth, ensuring even distribution of ambroxol across the pharyngeal mucosa. The duration of action has been shown to persist for at least 3 hours following administration, providing meaningful symptomatic relief throughout the day.
It is important to recognise the difference between ambroxol used as a mucolytic (to thin mucus in respiratory conditions) and its use in lozenge form for sore throat. When taken as tablets or syrup at doses of 30–120 mg daily, ambroxol acts systemically to reduce mucus viscosity. In contrast, the 20 mg lozenge delivers the active substance directly to the throat tissue, where its sodium channel-blocking properties provide the primary therapeutic benefit. This targeted delivery results in effective local analgesia without the higher systemic drug levels associated with oral or inhaled formulations.
What Should You Know Before Taking Mucoangin Citron?
Contraindications
Mucoangin Citron should not be used by anyone who is allergic (hypersensitive) to ambroxol hydrochloride or to any of the other ingredients in the lozenge. If you have previously experienced an allergic reaction to ambroxol in any formulation – whether as lozenges, tablets, syrup, or inhaled solution – you should avoid using this product. Allergic reactions to ambroxol can range from mild skin rashes to severe anaphylactic reactions, and the severity may increase with repeated exposure.
The medicine is not suitable for children under 12 years of age. There is insufficient clinical data to establish the safety and efficacy of ambroxol lozenges in younger children, and alternative sore throat treatments should be considered for this age group. Parents seeking sore throat relief for younger children should consult a pharmacist or doctor for age-appropriate options such as paracetamol oral suspension, throat sprays formulated for children, or honey-based remedies (for children over 1 year).
Warnings and Precautions
Before using Mucoangin Citron, speak to your doctor or pharmacist if you have any of the following conditions:
- Liver or kidney problems: Ambroxol is metabolised in the liver and excreted via the kidneys. Impaired hepatic or renal function may affect the clearance of the drug, and medical advice should be sought before use. While the systemic exposure from lozenges is lower than from oral tablets, caution is still warranted in patients with significant organ impairment.
- Sugar intolerance: Each lozenge contains 1.37 g of sorbitol (a source of fructose) and 6.3 mg of sucrose. People with hereditary fructose intolerance, a rare genetic condition that prevents the breakdown of fructose, should not take this medicine. Sorbitol may cause gastrointestinal discomfort and have a mild laxative effect.
- Oral ulcers or lesions: Mucoangin Citron is not intended for the treatment of painful conditions in the mouth such as mouth ulcers, aphthous stomatitis, or oral sores. The local anaesthetic effect may mask pain from underlying oral conditions that require specific treatment. If you have oral lesions, consult your doctor for appropriate management.
You may experience reduced sensation (numbness) in your mouth and throat as a result of the local anaesthetic effect. This is expected and temporary, but if it persists or causes concern, discontinue use and speak to your pharmacist. Be cautious when eating or drinking hot liquids while your mouth and throat are numb, as you may be at increased risk of accidental burns or choking.
Shortness of breath (dyspnoea) may occur due to underlying conditions such as throat or laryngeal swelling from infection or inflammation. This should be distinguished from the sensation of pressure or tightness in the throat that may result from the local anaesthetic effect of the lozenge. In rare cases, allergic reactions to ambroxol can also cause swelling of the mouth and throat (angioedema). If you experience difficulty breathing or feel that your throat is closing up, seek emergency medical attention immediately regardless of the suspected cause.
Pregnancy and Breastfeeding
Mucoangin Citron should not be used during pregnancy, particularly during the first trimester. Ambroxol crosses the placental barrier and enters the foetal circulation. While animal studies have not demonstrated teratogenic effects at therapeutic doses, there is insufficient clinical data in pregnant women to establish safety. The potential risks to the developing foetus have not been adequately evaluated, and the precautionary principle applies. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.
Ambroxol is excreted in breast milk. Therefore, Mucoangin Citron should not be used during breastfeeding. The potential effects on the nursing infant have not been adequately studied, and it is not possible to exclude a risk to the breastfed child. Alternative sore throat treatments that are compatible with breastfeeding should be considered. Your doctor or pharmacist can advise on suitable alternatives, which may include paracetamol, saltwater gargles, or throat sprays with a more established safety profile during lactation.
Driving and Operating Machinery
Mucoangin Citron has no known effect on the ability to drive or operate machinery. The local anaesthetic effect is confined to the oropharyngeal region and does not affect cognitive function, reaction time, or motor coordination. However, as with all medicines, you should be aware of how the product affects you individually before engaging in activities that require alertness. If you experience any unusual dizziness or drowsiness (not expected side effects), refrain from driving until you have discussed this with your doctor.
How Does Mucoangin Citron Interact with Other Drugs?
The potential for drug interactions with Mucoangin Citron lozenges is considered to be low. The 20 mg ambroxol dose delivered via a lozenge acts predominantly at the local level in the oropharyngeal cavity, with limited systemic absorption compared to oral tablets or syrups. This means that the circulating plasma levels of ambroxol following lozenge use are generally lower than those achieved with systemic formulations, reducing the likelihood of systemic drug-drug interactions.
Ambroxol in its systemic form (tablets, syrups) has been studied for potential interactions with several drug classes. At the systemic level, ambroxol may increase the concentration of certain antibiotics (such as amoxicillin, cefuroxime, and erythromycin) in bronchial secretions and lung tissue, which can be therapeutically beneficial in respiratory infections. However, this pharmacokinetic effect is primarily relevant to systemic ambroxol formulations at higher doses rather than to lozenges used for sore throat.
Although no specific drug interactions have been identified for the lozenge formulation, general caution is advised when using Mucoangin Citron alongside other throat or mouth treatments. Using multiple products with local anaesthetic properties simultaneously could lead to excessive numbness of the oropharyngeal area, potentially increasing the risk of accidental biting, burns from hot food or drink, or aspiration. It is advisable to use only one throat numbing product at a time.
Patients using antitussive (cough-suppressing) medicines should be aware that ambroxol has mucolytic properties that may theoretically conflict with cough suppression, though this interaction is not clinically significant at the lozenge dose. The mucolytic effect of ambroxol at 20 mg delivered topically is minimal compared to the 75–120 mg daily systemic doses used for respiratory indications.
| Drug / Class | Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Other local anaesthetic throat products | Additive effect | Low | Avoid concurrent use of multiple throat numbing products |
| Antitussives (cough suppressants) | Theoretical | Minimal | Generally safe; consult pharmacist if concerned |
| Antibiotics (amoxicillin, cefuroxime) | Potential enhancement | Low (lozenge form) | No dose adjustment needed; may enhance antibiotic penetration |
| NSAIDs (ibuprofen, naproxen) | No interaction | None | Safe to use together for pain relief |
| Paracetamol (acetaminophen) | No interaction | None | Safe to use together for pain relief |
If you are taking any prescription medicines, over-the-counter products, herbal remedies, or dietary supplements, always inform your doctor or pharmacist before starting Mucoangin Citron. This is particularly important if you are taking medicines for liver or kidney disease, as impaired organ function may affect the metabolism and clearance of ambroxol even at the lower systemic levels achieved through lozenge use.
What Is the Correct Dosage of Mucoangin Citron?
Always use Mucoangin Citron exactly as described in the patient information leaflet or as directed by your doctor or pharmacist. The recommended dosage is straightforward and designed for self-medication by adults and adolescents aged 12 years and over. No dose titration is required, and there is no need to take the medicine with food or water.
Adults and Adolescents (12 years and over)
Standard Dosage
Allow 1 lozenge (20 mg ambroxol hydrochloride) to dissolve slowly in the mouth when pain relief is needed. You may use up to a maximum of 6 lozenges per day. Do not chew or swallow the lozenge whole – allow it to dissolve completely for optimal local anaesthetic effect. The dissolving process typically takes several minutes and ensures even distribution of the active ingredient across the throat tissue.
Clinical data have demonstrated a rapid onset of action, with pain relief beginning within 20 minutes of starting to dissolve the lozenge. The analgesic effect persists for at least 3 hours, allowing for adequate spacing between doses throughout the day. There is no need to take the lozenges at fixed intervals; use them as needed when sore throat pain returns, while respecting the maximum daily limit of 6 lozenges.
Children
Children Under 12 Years
Mucoangin Citron should not be used in children under 12 years of age. The safety and efficacy of ambroxol lozenges have not been established in this age group. For sore throat in younger children, consult your doctor or pharmacist for age-appropriate alternatives such as paracetamol oral suspension, ibuprofen for children, or age-specific throat sprays.
For adolescents aged 12 to 17 years, the same dosage as adults applies: one lozenge dissolved slowly in the mouth as needed, with a maximum of 6 lozenges per day for no more than 3 consecutive days. Parents and caregivers should supervise the use of this medicine in adolescents to ensure the maximum daily dose is not exceeded.
Elderly Patients
No dose adjustment is required for elderly patients. However, elderly individuals with impaired liver or kidney function should consult their doctor before using Mucoangin Citron, as reduced organ function may affect the clearance of ambroxol. The standard adult dose of up to 6 lozenges per day applies, but particular attention should be paid to any signs of accumulation or adverse effects. Elderly patients should also be mindful of the temporary numbness effect in the mouth and throat, which may increase the risk of aspiration or difficulty swallowing in individuals with pre-existing swallowing disorders (dysphagia).
Duration of Treatment
| Patient Group | Single Dose | Maximum Daily Dose | Duration |
|---|---|---|---|
| Adults (18+ years) | 1 lozenge (20 mg) | 6 lozenges (120 mg) | Max 3 days |
| Adolescents (12–17 years) | 1 lozenge (20 mg) | 6 lozenges (120 mg) | Max 3 days |
| Children (under 12 years) | Not recommended | Not recommended | N/A |
| Elderly | 1 lozenge (20 mg) | 6 lozenges (120 mg) | Max 3 days |
Missed Dose
Since Mucoangin Citron is used on an as-needed basis for pain relief rather than at fixed scheduled times, there is no concept of a “missed dose.” Simply use a lozenge when you next experience sore throat pain, ensuring you do not exceed the maximum daily dose of 6 lozenges. There is no need to take a double dose to compensate for a period during which the medicine was not used.
Overdose
No symptoms specific to overdose with Mucoangin Citron have been reported in clinical trials or post-marketing surveillance. If you accidentally take more than the recommended daily dose of 6 lozenges, or if a child accidentally ingests the medicine, contact your doctor, hospital emergency department, or local poison control centre for assessment and advice. Symptoms of excessive ambroxol intake at systemic doses may include nausea, vomiting, and gastrointestinal discomfort, but clinically significant overdose from lozenge use alone is unlikely. Monitor for any unusual symptoms and seek medical advice if concerned.
What Are the Side Effects of Mucoangin Citron?
Like all medicines, Mucoangin Citron can cause side effects, although not everybody gets them. The side effects listed below are based on clinical trial data from 1,226 patients and post-marketing surveillance reports gathered since the product’s introduction to the market. Most side effects are mild and transient, resolving once use of the lozenge is discontinued.
- Allergic reaction with swelling of the face, lips, mouth, tongue, or throat (angioedema), which may cause a feeling of tightness in the throat, difficulty swallowing, or breathing problems
- Rapid-onset allergic reactions affecting the whole body (anaphylactic reaction, including anaphylactic shock)
- Severe skin rash, blistering, or peeling of the skin, particularly if accompanied by lesions in the mouth, throat, nose, eyes, or genitals
The severity of allergic reactions may increase if the medicine is taken again after a previous reaction, or if you take another medicine containing the same active substance (ambroxol) or a related compound (bromhexine). If you have experienced any allergic reaction to Mucoangin Citron, do not use it again and inform your doctor about the reaction.
Common
May affect up to 1 in 10 people
- Nausea
- Numbness of the mouth, tongue, and throat (oral and pharyngeal hypoaesthesia)
- Altered taste sensation (dysgeusia)
Uncommon
May affect up to 1 in 100 people
- Diarrhoea
- Indigestion (dyspepsia)
- Abdominal pain (upper gastrointestinal pain)
- Dry mouth
Rare
May affect up to 1 in 1,000 people
- Hypersensitivity reactions
- Skin rash and hives (urticaria)
- Throat dryness
Not Known
Frequency cannot be estimated from available data
- Anaphylactic reactions including anaphylactic shock
- Angioedema (rapid swelling under the skin and mucous membranes)
- Pruritus (itching)
- Severe skin reactions: erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalised exanthematous pustulosis (AGEP)
- Vomiting
The most commonly reported side effect – numbness of the mouth and throat – is a direct and expected consequence of the local anaesthetic mechanism of action. This sensation is temporary and resolves as the effect of the lozenge wears off, typically within a few hours. Most patients consider this effect to be a normal part of the medicine’s action rather than an unwanted side effect, though it should be noted as it may affect eating and drinking.
The gastrointestinal side effects (nausea, diarrhoea, dyspepsia) may be related in part to the sorbitol content of the lozenges. Sorbitol is known to have an osmotic effect in the gut and can cause bloating, flatulence, and loose stools, particularly when consumed in larger quantities. At the maximum dose of 6 lozenges per day, the total sorbitol intake from Mucoangin Citron would be 8.22 g, which is below the threshold that typically causes significant gastrointestinal symptoms in most individuals.
If you experience any side effects not listed above, or if any of the listed side effects become severe or persistent, consult your doctor or pharmacist. Reporting suspected adverse reactions after the medicine has been authorised is important, as it allows for continuous monitoring of the benefit-risk balance of the medicine. In many countries, patients and healthcare professionals can report suspected side effects directly to the national medicines regulatory authority.
How Should You Store Mucoangin Citron?
Proper storage of medicines is essential to maintain their efficacy and safety throughout their shelf life. Mucoangin Citron lozenges are packaged in aluminium/aluminium blister packs that protect the product from moisture and light. Following the storage guidelines below ensures that the medicine remains effective until the stated expiry date.
- Temperature: Store at or below 30°C (86°F). Do not refrigerate or freeze the lozenges, as temperature extremes may alter the physical properties of the tablet and affect dissolution.
- Keep out of reach: Store the medicine out of sight and reach of children to prevent accidental ingestion. The lemon flavour may be attractive to children, so particular care should be taken with storage.
- Expiry date: Do not use after the expiry date stated on the carton and blister foil. The expiry date refers to the last day of that month. Expired medicines may have reduced efficacy and should be returned to a pharmacy for safe disposal.
- Packaging: Keep the lozenges in their original aluminium/aluminium blister packaging until ready to use. Do not transfer to other containers, as this may compromise the protective barrier against moisture.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist about how to dispose of medicines that are no longer needed or have passed their expiry date. Many pharmacies and local authorities operate medicine take-back programmes. These measures help to protect the environment and prevent accidental exposure to discarded medicines.
What Does Mucoangin Citron Contain?
Understanding the full composition of your medicine is important, particularly if you have known allergies or intolerances to specific excipients (inactive ingredients). Below is a complete breakdown of the ingredients in Mucoangin Citron, along with explanations of their role in the formulation.
Active Ingredient
Each lozenge contains 20 mg of ambroxol hydrochloride. Ambroxol is a metabolite of bromhexine and has been used in clinical practice since the 1970s, primarily as a mucolytic agent for respiratory conditions. In lozenge form at the 20 mg dose, it acts as a local anaesthetic by blocking sodium channels in the oropharyngeal mucosa, providing direct pain relief for sore throat. Ambroxol also has documented anti-inflammatory and antioxidant properties, which may contribute to its overall therapeutic effect in acute pharyngitis.
Inactive Ingredients (Excipients)
- Lemon flavouring (contains sucrose) – provides the characteristic citrus taste that makes the lozenge more palatable during use
- Frescofort flavouring – contributes to the cooling, refreshing sensation in the mouth and throat
- Sorbitol (E420) – functions as both a sweetener and bulking agent; each lozenge contains 1.37 g of sorbitol, which is a sugar alcohol derived from glucose
- Sucralose – a non-caloric artificial sweetener that provides intense sweetness without affecting blood sugar levels
- Macrogol 6000 (polyethylene glycol 6000) – used as a binder in the tablet formulation to help maintain the structural integrity of the lozenge
- Talc – an anti-caking agent used during the manufacturing process to prevent the tablet material from sticking to equipment
Physical Description
Mucoangin Citron 20 mg lozenges are round, white tablets with bevelled edges and flat surfaces on both sides. They have a smooth texture and a mild lemon scent. The lozenges are supplied in aluminium/aluminium blister packs in the following sizes: 12, 18, 24, 30, 36, 42, and 48 lozenges. Not all pack sizes may be available in all markets – availability varies by country and distribution channel.
International Brand Names
Mucoangin Citron is authorised and marketed under various brand names across the European Economic Area. The product was developed by Opella Healthcare France SAS (formerly part of the Sanofi group) and is manufactured by Delpharm Reims S.A.S. in Reims, France. The following table shows the different brand names used in various countries:
| Country | Brand Name |
|---|---|
| Belgium, Luxembourg | Mucoangin Citron |
| Cyprus, Greece | Lysopadol |
| Denmark, Sweden | Mucoangin Citron |
| France | Lysopaïne Maux de Gorge Ambroxol Citron |
| Germany | Mucoangin gegen Halsschmerzen Zitrone |
| Ireland | Lysopadol Lemon |
| Italy | Zerinol Gola |
| Netherlands | Mucoangin Citroen |
| Spain | Lizipadol |
| Austria | Mucoangin Zitrone |
Frequently Asked Questions About Mucoangin Citron
Mucoangin Citron and Mucoangin Mint contain the same active ingredient (20 mg ambroxol hydrochloride) and have identical therapeutic effects. The only difference is the flavouring: Mucoangin Citron has a lemon flavour, while Mucoangin Mint has a mint flavour. The choice between them is entirely a matter of personal taste preference. Both provide the same fast-acting local anaesthetic relief for sore throat, with the same dosage recommendations, duration of use, and safety profile.
Yes, Mucoangin Citron can generally be used safely alongside paracetamol (acetaminophen) or ibuprofen for sore throat relief. Since Mucoangin Citron works locally as a throat anaesthetic, while paracetamol and ibuprofen work systemically as analgesics and anti-inflammatories, combining them can provide complementary pain relief through different mechanisms. However, always read the labels of all medicines and do not exceed the recommended doses of any individual product. If you are unsure about combining medicines, ask your pharmacist for advice.
The 3-day limitation is a standard recommendation for over-the-counter sore throat treatments. Most viral sore throats improve significantly within 3 to 5 days. If symptoms persist beyond 3 days, this may indicate a more serious condition such as a bacterial infection (e.g., group A streptococcal pharyngitis) that requires medical evaluation and potentially antibiotic treatment. Using Mucoangin Citron beyond 3 days without medical supervision could mask symptoms that need professional assessment. Additionally, prolonged local anaesthetic use may affect normal swallowing reflexes and oral sensation, and the underlying cause of the sore throat should be investigated.
Mucoangin Citron is sweetened primarily with sorbitol and sucralose rather than sugar, which makes it generally suitable for people with diabetes. Each lozenge contains only 6.3 mg of sucrose, which is a negligible amount that is unlikely to affect blood sugar control. However, each lozenge also contains 1.37 g of sorbitol, which provides approximately 2.6 kilocalories (sorbitol has a caloric value of 2.6 kcal/g). At the maximum dose of 6 lozenges per day, the total sorbitol intake would be 8.22 g, contributing approximately 21 kilocalories. This is within acceptable limits for most diabetic patients, but if you are managing diabetes closely, discuss with your doctor or pharmacist.
Clinical studies have demonstrated that Mucoangin Citron provides a rapid onset of pain relief, with statistically significant reduction in sore throat pain beginning within 20 minutes of starting to dissolve the lozenge. The analgesic effect lasts for at least 3 hours. For best results, allow the lozenge to dissolve slowly and completely in your mouth rather than chewing or swallowing it, as this ensures maximum contact between the active ingredient and the inflamed throat tissue. The gradual dissolution also provides a sustained release of ambroxol across the pharyngeal mucosa.
Mucoangin Citron contains a small amount of sucrose (6.3 mg per lozenge) within the lemon flavouring, but it is primarily sweetened with sorbitol (1.37 g per lozenge) and sucralose (an artificial sweetener). The sucrose content is negligible from a dietary perspective. People with hereditary fructose intolerance should not take this medicine due to the sorbitol content, as sorbitol is metabolised to fructose in the body. The sorbitol may also cause gastrointestinal discomfort or have a mild laxative effect in some individuals, particularly when multiple lozenges are used throughout the day.
References
This article is based on the approved product information (Summary of Product Characteristics and Patient Information Leaflet) for Mucoangin Citron, supplemented by peer-reviewed clinical evidence and international guidelines.
- European Medicines Agency (EMA). Ambroxol and bromhexine: Article 31 referral – Assessment report. EMA/775748/2015. EMA Pharmacovigilance Risk Assessment Committee, 2016.
- de Mey C, Patel J, Engel LM, et al. Efficacy and safety of ambroxol lozenges in the treatment of acute uncomplicated sore throat – A pooled analysis. International Journal of Clinical Practice. 2008;62(10):1586–1592.
- Fischer J, Pschorn U, Vix JM, et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Arzneimittelforschung. 2002;52(4):256–263.
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List. Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Sore throat (acute): antimicrobial prescribing. NICE Guideline [NG84]. Updated 2023.
- British National Formulary (BNF). Oropharyngeal anti-infective drugs and local anaesthetics. London: BMJ Group and Pharmaceutical Press; 2025.
- Opella Healthcare France SAS. Mucoangin Citron 20 mg lozenges – Summary of Product Characteristics. Last revised September 2023.
- Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opinion on Drug Metabolism & Toxicology. 2008;4(8):1119–1129.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed physicians and pharmacists with expertise in clinical pharmacology, otolaryngology, and general practice. Our content follows the GRADE evidence framework and adheres to international guidelines from WHO, EMA, NICE, and the BNF.
- Evidence Level 1A – Systematic reviews and RCTs
- GRADE framework for evidence quality
- Independent – No commercial funding
- Peer-reviewed by specialist physicians
- Initial review by clinical pharmacologist
- Cross-checked against approved SmPC/PIL
- Accessibility review (WCAG 2.2 AAA)
- Regular updates based on new evidence